PHP
WGS icon

Parkman Healthcare Partners’s GeneDx Holdings WGS Stock Holding History

Parkman Healthcare Partners’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26M Buy
50,778
+11,506
+29% +$1.05M 0.34% 73
2025
Q4 		$5.11M Sell
39,272
-5,978
-13% -$821K 0.49% 62
2025
Q3 		$4.88M Sell
45,250
-129,750
-74% -$14.1M 0.51% 64
2025
Q2 		$16.2M Buy
+175,000
New +$13.7M 1.86% 18

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parkman Healthcare Partners's WGS Position: Q1 2026 in Review

Parkman Healthcare Partners increased its GeneDx Holdings (WGS) stake by 29% in Q1 2026, buying an estimated $1.05M and bringing the position to 50,778 shares worth $3.26M. The position accounts for 0.34% of the portfolio, ranked #73.

Parkman Healthcare Partners first reported a position in WGS in Q2 2025 and has held it in 4 quarters since. The position peaked at $16.2M in Q2 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Parkman Healthcare Partners held 50,778 shares of GeneDx Holdings worth $3.26M as of Q1 2026.
  • Parkman Healthcare Partners bought 11,506 GeneDx Holdings shares in Q1 2026, an estimated $1.05M.
  • GeneDx Holdings made up 0.34% of Parkman Healthcare Partners's portfolio in Q1 2026, its #73 holding.
  • Parkman Healthcare Partners first reported a position in GeneDx Holdings in Q2 2025 and has held it in 4 quarters since.
  • Parkman Healthcare Partners's GeneDx Holdings position peaked at $16.2M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.